By leveraging novel transgenic mice in which BTN3A1 was specifically expressed in dendritic cells, Payne et al. demonstrated an elevated malignant progression which paralleled the decreased infiltration and effector activity of αβ T cells in the setting of ovarian cancer. The gene discussed is BTN3A1; the disease is ovarian cancer.